Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Jeong-Chan Ra maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This prosecution is managed by 1 distinct examiner. Additionally, the 1 pending office action is assigned to 1 distinct art unit. These figures reflect a focused prosecution strategy where all active matters are concentrated under a single point of review within the USPTO.
The busiest examiner for this portfolio is MOSS, NATALIE M, who is responsible for 1 pending office action. This matches the total of 1 pending office action for the entire portfolio. For a practitioner, this means that the prosecution results depend on the 1 distinct examiner and the 1 distinct art unit identified. Navigating the specific requirements of MOSS, NATALIE M is the current task for the applicant. The presence of 1 distinct art unit indicates that the subject matter is specialized and does not span multiple technical divisions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SMALL, KATHERINE R | 1 | 69.4% | +29.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17784740 | METHOD FOR PREPARING MESENCHYMAL STEM CELLS HAVING IMPROVED VIABILITY THROUGH ANTI-CANCER VIRUS INTRODUCTION | SMALL, KATHERINE R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17784740 | METHOD FOR PREPARING MESENCHYMAL STEM CELLS HAVING IMPROVED VIABILITY THROUGH ANTI-CANCER VIRUS INTRODUCTION | SMALL, KATHERINE R | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17784740 | METHOD FOR PREPARING MESENCHYMAL STEM CELLS HAVING IMPROVED VIABILITY THROUGH ANTI-CANCER VIRUS INTRODUCTION | SMALL, KATHERINE R | 1633 | §102§103 | Non-Final OA | — | Pending | Jun 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJeong Chan Ra has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Katherine R Small has the most, with 1 of Jeong Chan Ra's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
